544 related articles for article (PubMed ID: 25841712)
1. Staging and response assessment in lymphomas: the new Lugano classification.
Cheson BD
Chin Clin Oncol; 2015 Mar; 4(1):5. PubMed ID: 25841712
[TBL] [Abstract][Full Text] [Related]
2. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.
Cheson BD; Fisher RI; Barrington SF; Cavalli F; Schwartz LH; Zucca E; Lister TA; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
J Clin Oncol; 2014 Sep; 32(27):3059-68. PubMed ID: 25113753
[TBL] [Abstract][Full Text] [Related]
3.
Tamayo P; Martín A; Díaz L; Cabrero M; García R; García-Talavera P; Caballero D
Rev Esp Med Nucl Imagen Mol; 2017; 36(5):312-321. PubMed ID: 28483374
[TBL] [Abstract][Full Text] [Related]
4. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.
Barrington SF; Mikhaeel NG; Kostakoglu L; Meignan M; Hutchings M; Müeller SP; Schwartz LH; Zucca E; Fisher RI; Trotman J; Hoekstra OS; Hicks RJ; O'Doherty MJ; Hustinx R; Biggi A; Cheson BD
J Clin Oncol; 2014 Sep; 32(27):3048-58. PubMed ID: 25113771
[TBL] [Abstract][Full Text] [Related]
5. PET/CT: appropriate application in lymphoma.
Wang X
Chin Clin Oncol; 2015 Mar; 4(1):4. PubMed ID: 25841711
[TBL] [Abstract][Full Text] [Related]
6. [Update on the use of FDG-PET/CT in malignant lymphoma].
Terauchi T
Rinsho Ketsueki; 2016; 57(10):2008-2012. PubMed ID: 27795508
[TBL] [Abstract][Full Text] [Related]
7. High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma.
Ngeow JYY; Quek RHH; Ng DCE; Hee SW; Tao M; Lim LC; Tan YH; Lim ST
Ann Oncol; 2009 Sep; 20(9):1543-1547. PubMed ID: 19474116
[TBL] [Abstract][Full Text] [Related]
8. PET/CT for Staging; Past, Present, and Future.
El-Galaly TC; Gormsen LC; Hutchings M
Semin Nucl Med; 2018 Jan; 48(1):4-16. PubMed ID: 29195617
[TBL] [Abstract][Full Text] [Related]
9. PET/CT for Lymphoma Post-therapy Response Assessment in Other Lymphomas, Response Assessment for Autologous Stem Cell Transplant, and Lymphoma Follow-up.
Karls S; Shah H; Jacene H
Semin Nucl Med; 2018 Jan; 48(1):37-49. PubMed ID: 29195616
[TBL] [Abstract][Full Text] [Related]
10. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
Berthet L; Cochet A; Kanoun S; Berriolo-Riedinger A; Humbert O; Toubeau M; Dygai-Cochet I; Legouge C; Casasnovas O; Brunotte F
J Nucl Med; 2013 Aug; 54(8):1244-50. PubMed ID: 23674577
[TBL] [Abstract][Full Text] [Related]
11. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma?
van Hamersvelt HP; Kwee TC; Fijnheer R; Beek FJ; de Klerk JM; Nievelstein RA
J Comput Assist Tomogr; 2014; 38(4):620-5. PubMed ID: 24681861
[TBL] [Abstract][Full Text] [Related]
12. Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma.
McCarten KM; Nadel HR; Shulkin BL; Cho SY
Pediatr Radiol; 2019 Oct; 49(11):1545-1564. PubMed ID: 31620854
[TBL] [Abstract][Full Text] [Related]
13. A comparison of clinical staging using the Lugano versus Ann Arbor classifications in Japanese patients with Hodgkin lymphoma.
Makita S; Maruyama D; Maeshima AM; Taniguchi H; Yuda S; Toyoda K; Yamauchi N; Fukuhara S; Munakata W; Kobayashi Y; Kurihara H; Izutsu K; Tobinai K
Asia Pac J Clin Oncol; 2020 Jun; 16(3):108-114. PubMed ID: 31802636
[TBL] [Abstract][Full Text] [Related]
14. Revised staging system for malignant lymphoma based on the Lugano classification.
Munakata W; Terauchi T; Maruyama D; Nagai H
Jpn J Clin Oncol; 2019 Oct; 49(10):895-900. PubMed ID: 31504700
[TBL] [Abstract][Full Text] [Related]
15. Whole body magnetic resonance with diffusion weighted sequence with body signal suppression compared to (18)F-FDG PET/CT in newly diagnosed lymphoma.
Ferrari C; Minoia C; Asabella AN; Nicoletti A; Altini C; Antonica F; Ficco M; Guarini A; Maggialetti N; Rubini G
Hell J Nucl Med; 2014; 17 Suppl 1():40-9. PubMed ID: 24392468
[TBL] [Abstract][Full Text] [Related]
16. PET/CT for therapy response assessment in lymphoma.
Hutchings M; Barrington SF
J Nucl Med; 2009 May; 50 Suppl 1():21S-30S. PubMed ID: 19380407
[TBL] [Abstract][Full Text] [Related]
17. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma.
El-Galaly TC; d'Amore F; Mylam KJ; de Nully Brown P; Bøgsted M; Bukh A; Specht L; Loft A; Iyer V; Hjorthaug K; Nielsen AL; Christiansen I; Madsen C; Johnsen HE; Hutchings M
J Clin Oncol; 2012 Dec; 30(36):4508-14. PubMed ID: 23150698
[TBL] [Abstract][Full Text] [Related]
18. PET/CT, MR, and PET/MR in Lymphoma and Melanoma.
Schwenzer NF; Pfannenberg AC
Semin Nucl Med; 2015 Jul; 45(4):322-31. PubMed ID: 26050659
[TBL] [Abstract][Full Text] [Related]
19. Imaging of non-Hodgkin lymphomas: diagnosis and response-adapted strategies.
El-Galaly TC; Hutchings M
Cancer Treat Res; 2015; 165():125-46. PubMed ID: 25655608
[TBL] [Abstract][Full Text] [Related]
20. Role of PET in lymphoma.
Schwaiger M; Wieder H
Chang Gung Med J; 2005 May; 28(5):315-25. PubMed ID: 16086546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
